Safety and Efficacy of Ledipasvir–Sofosbuvir With or Without Ribavirin for Chronic Hepatitis C in Children Ages 6‐11
Sign Up to like & getrecommendations! Published in 2018 at "Hepatology"
DOI: 10.1002/hep.30123
Abstract: Currently, there are no interferon‐free treatments available for hepatitis C virus (HCV)–infected patients younger than 12 years. We evaluated the safety and effectiveness of the all‐oral regimen ledipasvir–sofosbuvir ± ribavirin in HCV‐infected children aged 6… read more here.
Keywords: hepatitis; hcv; safety; sofosbuvir ... See more keywords
Synergistic antiviral activity of Sofosbuvir and type‐I interferons (α and β) against Zika virus
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Medical Virology"
DOI: 10.1002/jmv.24932
Abstract: Zika virus (ZIKV) is transmitted by mosquitoes and causes Dengue‐like illness, neurological symptoms such as Guillain‐Barré Syndrome and microcephaly in children born to infected pregnant mothers. Recently, the World Health Organization (WHO) declared ZIKV infection… read more here.
Keywords: combination; antiviral activity; sofosbuvir; zikv ... See more keywords
Ledipasvir/Sofosbuvir: A Review in Chronic Hepatitis C
Sign Up to like & getrecommendations! Published in 2018 at "Drugs"
DOI: 10.1007/s40265-018-0864-z
Abstract: Oral once-daily, fixed-dose, ledipasvir/sofosbuvir (Harvoni®) [± ribavirin] is approved in several countries for the treatment of chronic hepatitis C (CHC) in adults and adolescents aged 12 to read more here.
Keywords: ribavirin; infection; sofosbuvir; ledipasvir sofosbuvir ... See more keywords
Doubled dosage of sofosbuvir is expected for inhibiting Zika virus infection.
Sign Up to like & getrecommendations! Published in 2017 at "Asian Pacific journal of tropical medicine"
DOI: 10.1016/j.apjtm.2017.06.012
Abstract: Sofosbuvir is a new antiviral drug that has been recommended for management of hepatitis C virus (HCV) for a few years. New researches support that sofosbuvir might be useful for the management of Zika virus… read more here.
Keywords: sofosbuvir; dosage; zika virus; virus infection ... See more keywords
The clinically approved antiviral drug sofosbuvir inhibits Zika virus replication
Sign Up to like & getrecommendations! Published in 2017 at "Scientific Reports"
DOI: 10.1038/srep40920
Abstract: Zika virus (ZIKV) is a member of the Flaviviridae family, along with other agents of clinical significance such as dengue (DENV) and hepatitis C (HCV) viruses. Since ZIKV causes neurological disorders during fetal development and… read more here.
Keywords: sofosbuvir inhibits; sofosbuvir; drug; clinically approved ... See more keywords
Effectiveness and safety of sofosbuvir‐based therapy against chronic hepatitis C infection after successful kidney transplantation
Sign Up to like & getrecommendations! Published in 2019 at "Transplant Infectious Disease"
DOI: 10.1111/tid.13090
Abstract: Direct‐acting antivirals (DAAs), including sofosbuvir (SOF), are recommended for treatment of chronic hepatitis C virus (HCV) infection. However, few studies have investigated the effectiveness and safety of new DAAs in kidney transplant recipients (KTRs). read more here.
Keywords: effectiveness safety; infection; sofosbuvir; chronic hepatitis ... See more keywords
Cell Culture Studies of the Efficacy and Barrier to Resistance of Sofosbuvir-Velpatasvir and Glecaprevir-Pibrentasvir against Hepatitis C Virus Genotypes 2a, 2b, and 2c
Sign Up to like & getrecommendations! Published in 2019 at "Antimicrobial Agents and Chemotherapy"
DOI: 10.1128/aac.01888-19
Abstract: The introduction of highly efficient therapies with direct-acting antivirals (DAA) for patients with chronic hepatitis C virus (HCV) infection offers exceptional opportunities to globally control this deadly disease. For achieving this ambitious goal, it is… read more here.
Keywords: glecaprevir pibrentasvir; resistance; virus; sofosbuvir ... See more keywords
Sofosbuvir-based regimen is safe and effective for hepatitis C infected patients with stage 4–5 chronic kidney disease: a systematic review and meta-analysis
Sign Up to like & getrecommendations! Published in 2019 at "Virology Journal"
DOI: 10.1186/s12985-019-1140-x
Abstract: BackgroundWhether sofosbuvir is suitable for hepatitis C virus (HCV) infected patients with severe renal impairment is inconclusive. This systematic review aims to evaluate the safety and effectiveness of SOF-based regimen in the setting of stage… read more here.
Keywords: sofosbuvir; disease; infected patients; based regimen ... See more keywords
Initial results of efficacy and safety of Sofosbuvir among Pakistani Population: A real life trial - Hepatitis Eradication Accuracy Trial of Sofosbuvir (HEATS)
Sign Up to like & getrecommendations! Published in 2017 at "Pakistan Journal of Medical Sciences"
DOI: 10.12669/pjms.331.12352
Abstract: Objective: The uridine nucleotide analogue sofosbuvir is a selective inhibitor of hepatitis C virus (HCV) NS5B polymerase approved for the treatment of chronic HCV infection with genotypes 1 – 4. The objective of the study… read more here.
Keywords: trial; hepatitis; efficacy safety; results efficacy ... See more keywords
Impact of list price changes on out-of-pocket costs and adherence in four high-rebate specialty drugs
Sign Up to like & getrecommendations! Published in 2023 at "PLOS ONE"
DOI: 10.1371/journal.pone.0280570
Abstract: Background Insurers manage the cost of specialty medicines via rebates, however it is unclear if the savings are passed on to patients, and whether reducing rebates may lead to changes in patient out-of-pocket (OOP) costs… read more here.
Keywords: patient oop; oop costs; list price; sofosbuvir ... See more keywords
Cost-Effectiveness Analysis of Pan-Genotypic Sofosbuvir-Based Regimens for Treatment of Chronic Hepatitis C Genotype 1 Infection in China
Sign Up to like & getrecommendations! Published in 2021 at "Frontiers in Public Health"
DOI: 10.3389/fpubh.2021.779215
Abstract: Background: Hepatitis C virus (HCV) genotype 1 is the most prevalent HCV infection in China. Sofosbuvir-based direct antiviral agent (DAA) regimens are the current mainstays of treatment. Sofosbuvir/velpatasvir (SOF/VEL) and sofosbuvir/ledipasvir (SOF/LDV) regimens became reimbursable… read more here.
Keywords: sof vel; genotype; sof; cost ... See more keywords